SG149872A1 - Antagonists of the bradykinin b1 receptor - Google Patents

Antagonists of the bradykinin b1 receptor

Info

Publication number: SG149872A1
Authority: SG; Singapore
Prior art keywords: bradykinin; antagonists; receptor; present; peptides
Prior art date: 2003-10-22

Application number

SG200900445-8A

Other languages

English (en)

Inventor

Gordon Ng

Yue-Sheng Li

Colin V Gegg

Jr Benny C Askew

Thomas Storz

Yuelie Lu

Amico Derin C D

Mark A Jaronsinski

Chuan-Fa Liu

Qi Huang

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-22

Filing date

2004-10-22

Publication date

2009-02-27

2004-10-22 Application filed by Amgen Inc filed Critical Amgen Inc

2009-02-27 Publication of SG149872A1 publication Critical patent/SG149872A1/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/043—Kallidins; Bradykinins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/18—Kallidins; Bradykinins; Related peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Virology (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Addiction (AREA)
Hematology (AREA)

SG200900445-8A 2003-10-22 2004-10-22 Antagonists of the bradykinin b1 receptor SG149872A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US51391303P	2003-10-22	2003-10-22
US53892904P	2004-01-24	2004-01-24
US10/972,236 US7605120B2 (en)	2003-10-22	2004-10-21	Antagonists of the brandykinin B1 receptor

Publications (1)

Publication Number	Publication Date
SG149872A1 true SG149872A1 (en)	2009-02-27

Family

ID=34990807

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG200900445-8A SG149872A1 (en)	2003-10-22	2004-10-22	Antagonists of the bradykinin b1 receptor

Country Status (15)

Country	Link
US (4)	US7605120B2 (es)
EP (1)	EP1677830B1 (es)
JP (1)	JP4896728B2 (es)
KR (2)	KR100860654B1 (es)
AU (1)	AU2004285467A1 (es)
BR (1)	BRPI0415755A (es)
CA (1)	CA2545499A1 (es)
EA (1)	EA009294B1 (es)
EC (1)	ECSP066575A (es)
ES (1)	ES2395546T3 (es)
IL (1)	IL175084A0 (es)
MA (1)	MA28160A1 (es)
NO (1)	NO20062198L (es)
SG (1)	SG149872A1 (es)
WO (1)	WO2005042027A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005105057A1 (en) *	2004-04-23	2005-11-10	Amgen Inc.	Sustained release formulations
US20080095849A1 (en) *	2005-04-25	2008-04-24	Amgen Inc.	Peptide sustained release compositions and uses thereof
EP2573111A1 (en)	2006-04-20	2013-03-27	Amgen Inc.	GLP-1 compounds
US7403325B2 (en) *	2006-05-19	2008-07-22	Xerox Corporation	Electrophoretic display device
CA2687141C (en)	2007-05-22	2014-04-01	Amgen Inc.	Compositions and methods for producing bioactive fusion proteins
WO2008153967A1 (en) *	2007-06-08	2008-12-18	Contec Therapeutics, Inc.	Bk1 antagonist conjugates
US20100048913A1 (en)	2008-03-14	2010-02-25	Angela Brodie	Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20110118219A1 (en)	2008-03-25	2011-05-19	University Of Maryland, Baltimore	Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
BR122018013284B1 (pt)	2008-10-29	2022-03-03	Ablynx N.V	Formulações de moléculas de ligação ao antígeno de domínio único, seu método de formulação e seu uso, kit ou artigo de fabricação, bem como método para preparar uma formulação reconstituída contendo uma molécula de sdab
AU2009314311B2 (en)	2008-10-29	2013-01-10	Ablynx N.V.	Methods for purification of single domain antigen binding molecules
EP2393827B1 (en)	2009-02-05	2015-10-07	Tokai Pharmaceuticals, Inc.	Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
EP3385279B1 (en)	2009-03-20	2020-02-26	Amgen Inc.	Carrier immunoglobulins and uses thereof
WO2010110887A1 (en) *	2009-03-24	2010-09-30	Robert Shorr	Fatty acids
AU2011277983C1 (en) *	2010-07-16	2016-09-29	Ablynx Nv	Modified single domain antigen binding molecules and uses thereof
JP6159660B2 (ja)	2010-09-22	2017-07-05	アムジエン・インコーポレーテツド	担体としての免疫グロブリンおよびその使用
DE102011118029A1 (de) *	2011-06-20	2012-12-20	Universität Leipzig	Modifizierte antibiotische Peptide mit variabler systemischer Freisetzung
US9884067B2 (en)	2013-03-14	2018-02-06	University Of Maryland, Baltimore	Androgen receptor down-regulating agents and uses thereof
US9808472B2 (en)	2013-08-12	2017-11-07	Tokai Pharmaceuticals, Inc.	Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
US11401303B2 (en) *	2020-06-15	2022-08-02	Taian City Qihang Biotechnology Co.	Synthetic peptide BRAP and application in preparation of anti-inflammatory drug for COVID-19 thereof
CA3151034A1 (en) *	2021-03-03	2022-09-03	Kashiv Biosciences, Llc	Bioassay method for compounds useful to treat pain

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2435642A1 (de)	1974-07-24	1976-02-05	Hoffmann La Roche	Traegermaterial
US4693993A (en) *	1985-06-13	1987-09-15	Stewart John M	Bradykinin antagonist peptides
US4801613A (en) *	1985-06-13	1989-01-31	Nova Technology Limited Partnership	Bradykinin antagonist peptides
US4923963A (en) *	1987-09-02	1990-05-08	Nova Technology Limited Partnership	Bradykinin antagonist peptides
EP0318162A3 (en)	1987-11-25	1990-11-07	Texaco Development Corporation	Novel bismaleimide derivatives
US5648333A (en) *	1988-11-24	1997-07-15	Hoechst Aktiengesellschaft	Peptides having bradykinin antagonist action
US5252714A (en) *	1990-11-28	1993-10-12	The University Of Alabama In Huntsville	Preparation and use of polyethylene glycol propionaldehyde
US5416191A (en) *	1991-04-01	1995-05-16	Cortech, Inc.	Bradykinin antagonists
US5863899A (en) *	1991-04-01	1999-01-26	Cortech, Inc.	Bradykinin antagonists
CA2106762C (en) *	1991-04-19	2000-10-10	Donald J. Kyle	Bradykinin antagonist peptides
US6407207B1 (en) *	1992-03-30	2002-06-18	Merck & Co., Inc.	Cloned and expressed human bradykinin BK-2 receptor
US5521158A (en) *	1992-10-08	1996-05-28	Scios Nova Inc.	Pseudopeptide bradykinin receptor antagonists
US5541286A (en) *	1992-10-08	1996-07-30	Scios Nova Inc.	Bradykinin antagonist pseudopeptide derivatives of olefinic aminoalkanoic acids
US5955430A (en) *	1993-09-24	1999-09-21	University Of Southern California	Use of angiotensin II fragments and analogs thereof in tissue repair
DE69533704D1 (de) *	1994-03-09	2004-12-02	Cortech Inc	Bradykinin-antagonist peptide mit n-substituierten glycinen
US5648336A (en) *	1994-11-18	1997-07-15	University Of Colorado	Bradykinin antagonist peptides containing indane-substituted amino acids
US5834431A (en) *	1995-09-08	1998-11-10	Cortech, Inc.	Des-Arg9 -BK antagonists
US5849863A (en) *	1995-09-08	1998-12-15	University Of Colorado	Cytolytic bradykinin antagonists
AU3935897A (en)	1996-08-19	1998-03-06	Universite De Sherbrooke	B1-bradykinin receptor antagonists and use thereof
JP3274076B2 (ja)	1996-12-16	2002-04-15	セイコーインスツルメンツ株式会社	ペプチド断片を得る方法
US5935932A (en) *	1997-06-13	1999-08-10	University Technology Corporation	Bradykinin antagonists containing pentafluorophenylalanine
US6388054B1 (en) *	1998-08-20	2002-05-14	John M. Stewart	Anti-cancer compounds
US6875741B2 (en) *	1998-09-02	2005-04-05	Renuka Pillutla	Insulin and IGF-1 receptor agonists and antagonists
WO2001062827A2 (en)	2000-02-22	2001-08-30	Shearwater Corporation	N-maleimidyl polymer derivatives
MXPA03010210A (es) *	2001-05-11	2004-03-10	Amgen Inc	Peptidos y moleculas relacionadas que se enlazan a tall-1.
US7138370B2 (en) *	2001-10-11	2006-11-21	Amgen Inc.	Specific binding agents of human angiopoietin-2
EP1549269A4 (en) *	2002-10-09	2010-10-06	Cerulean Pharma Inc	CYCLODEXTRIN BASED MATERIALS, COMPOSITIONS AND ITS USE
WO2004080412A2 (en) *	2003-03-07	2004-09-23	The University Of Toledo	Paclitaxel hybrid derivatives

2004
- 2004-10-21 US US10/972,236 patent/US7605120B2/en not_active Expired - Fee Related
- 2004-10-22 KR KR1020087002104A patent/KR100860654B1/ko not_active IP Right Cessation
- 2004-10-22 WO PCT/US2004/034976 patent/WO2005042027A2/en active Application Filing
- 2004-10-22 SG SG200900445-8A patent/SG149872A1/en unknown
- 2004-10-22 KR KR1020067009876A patent/KR20060105757A/ko active Search and Examination
- 2004-10-22 ES ES04796039T patent/ES2395546T3/es active Active
- 2004-10-22 AU AU2004285467A patent/AU2004285467A1/en not_active Abandoned
- 2004-10-22 EA EA200600817A patent/EA009294B1/ru not_active IP Right Cessation
- 2004-10-22 BR BRPI0415755-9A patent/BRPI0415755A/pt not_active IP Right Cessation
- 2004-10-22 EP EP04796039A patent/EP1677830B1/en active Active
- 2004-10-22 CA CA002545499A patent/CA2545499A1/en not_active Abandoned
- 2004-10-22 JP JP2006536809A patent/JP4896728B2/ja active Active
2006
- 2006-04-20 IL IL175084A patent/IL175084A0/en unknown
- 2006-05-12 MA MA29025A patent/MA28160A1/fr unknown
- 2006-05-15 NO NO20062198A patent/NO20062198L/no not_active Application Discontinuation
- 2006-05-18 EC EC2006006575A patent/ECSP066575A/es unknown
2008
- 2008-04-08 US US12/082,219 patent/US8278280B2/en not_active Expired - Fee Related
- 2008-04-08 US US12/082,224 patent/US8288351B2/en not_active Expired - Fee Related
- 2008-04-09 US US12/082,395 patent/US20090048149A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ECSP066575A (es)	2006-10-17
US8288351B2 (en)	2012-10-16
EP1677830A2 (en)	2006-07-12
US20090137452A1 (en)	2009-05-28
WO2005042027A2 (en)	2005-05-12
AU2004285467A2 (en)	2005-05-12
US20090048149A1 (en)	2009-02-19
KR20060105757A (ko)	2006-10-11
US20090137483A1 (en)	2009-05-28
KR20080015054A (ko)	2008-02-15
US20050215470A1 (en)	2005-09-29
IL175084A0 (en)	2006-08-20
WO2005042027A3 (en)	2006-02-09
JP4896728B2 (ja)	2012-03-14
EP1677830B1 (en)	2012-10-17
KR100860654B1 (ko)	2008-09-26
JP2007526240A (ja)	2007-09-13
ES2395546T3 (es)	2013-02-13
EA009294B1 (ru)	2007-12-28
NO20062198L (no)	2006-07-18
BRPI0415755A (pt)	2006-12-19
CA2545499A1 (en)	2005-05-12
US7605120B2 (en)	2009-10-20
EA200600817A1 (ru)	2006-12-29
US8278280B2 (en)	2012-10-02
MA28160A1 (fr)	2006-09-01
AU2004285467A1 (en)	2005-05-12

Publication	Publication Date	Title
SG149872A1 (en)	2009-02-27	Antagonists of the bradykinin b1 receptor
IL163573A0 (en)	2005-12-18	Conjugates of therapeutic or cytotoxic agents and biologically active peptides
MXPA05002814A (es)	2005-05-27	Formulacion para agentes lipofilicos.
WO2005107726A3 (en)	2006-08-24	Method for the treatment of back pain
HK1077518A1 (en)	2006-02-17	Peptides that modulate nerve growth factor (ngf) activity, their compositions and use
GB2431346C (en)	2010-02-17	A combination composition comprising paracetamol and ibuprofen
WO2003096990A3 (en)	2004-02-26	Protein cages for the delivery of medical imaging and therapy
DE60223254D1 (de)	2007-12-13	Verzögert freisetzende formulierungen von oxymorphon
PL1656372T3 (pl)	2013-08-30	Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym
MXPA06013133A (es)	2007-05-23	Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina.
WO2005011590A3 (en)	2007-09-20	Compositions and methods for restoring sensitivity to treatment with her2 antagonists
IL166596A0 (en)	2006-01-15	Salt of morphine-6-glucoronide
TNSN06113A1 (en)	2007-11-15	Antagonists of the bradykinin b1 receptor
IL174134A0 (en)	2006-08-01	Use of a protein in the preparation of a medicament for treatment of fibrotic diseases
MX2007014803A (es)	2008-04-21	Composiciones que penetran el nucleo celular.
GB0326221D0 (en)	2003-12-17	Therapeutic agents,compositions,preparations and uses
RS20050603A (en)	2007-09-21	New combinations and new application of pharmaceutically active compounds
GB0304549D0 (en)	2003-04-02	Biologically and therapeutically active agents against HIV-1
GB0218483D0 (en)	2002-09-18	Biologically and therapeutically active agents against HIV-1
GB0410138D0 (en)	2004-06-09	Biologically and therapeutically active agents against HIV-1
WO2005011589A3 (en)	2006-01-26	Drug delivery methods and devices
GB0305644D0 (en)	2003-04-16	Biologically and therapeutically active agents
GB0306345D0 (en)	2003-04-23	Biologically and therapeutically active agents
SI1668027T1 (sl)	2010-09-30	Ciklični peptidi delujoči kot antagonisti urotenzina ii
WO2005056581A3 (en)	2005-10-13	Peptide able to specifically bind a chemokine receptor and use thereof